MDMA or related drug-induced anxiety disorder (Q40434): Difference between revisions

@@ description / pt-br / description / pt-br @@
+Transtorno de ansiedade induzido por MDMA ou drogas relacionadas, incluindo MDA é caracterizado por sintomas ansiosos (p. ex., apreensão ou preocupação, medo, sintomas fisiológicos de ativação autonômica excessiva, comportamento de evitação) que se desenvolvem durante ou logo após intoxicação por MDMA ou drogas relacionadas. A intensidade ou duração dos sintomas é consideravelmente maior do que sintomas ansiosos característicos da intoxicação por MDMA ou drogas relacionadas, incluindo MDA. A quantidade e duração do uso de MDMA ou drogas relacionadas devem ser capazes de produzir sintomas de ansiedade. Os sintomas não são mais bem explicados por um transtorno mental primário (p.ex., transtorno de ansiedade e relacionado ao medo, transtorno depressivo com sintomas ansiosos proeminentes), como pode ser o caso se os sintomas de ansiedade precederam o início do uso de MDMA ou drogas relacionadas, se os sintomas persistem por um período de tempo considerável após a cessação do uso de MDMA ou drogas relacionadas, ou se há outra evidência de um transtorno mental primário preexistente com sintomas ansiosos (p. ex., história de episódios anteriores não associados ao uso de MDMA ou drogas relacionadas).
@@ description / en / description / en @@
+MDMA or related drug-induced anxiety disorder, including MDA is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of MDMA or related drug intoxication, including MDA. The amount and duration of MDMA or related drug use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use).
@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/325981339
@@ Property / Canonical URI: https://id.who.int/icd/entity/325981339 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:6C4C.71
@@ Property / CURIE: CID11:6C4C.71 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-6C4C.71
@@ Property / Canary Token: dki-india-6C4C.71 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank
@@ Property / Linked ICD 10 @@
+F15.8
@@ Property / Linked ICD 10: F15.8 / rank @@
+Normal rank

Latest revision as of 06:14, 13 August 2026

MDMA or related drug-induced anxiety disorder, including MDA is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of MDMA or related drug intoxication, including MDA. The amount and duration of MDMA or related drug use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use).

Language	Label	Description	Also known as
default for all languages	6C4C.71
English	MDMA or related drug-induced anxiety disorder	MDMA or related drug-induced anxiety disorder, including MDA is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication with MDMA or related drugs. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of MDMA or related drug intoxication, including MDA. The amount and duration of MDMA or related drug use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the MDMA or related drug use, if the symptoms persist for a substantial period of time after cessation of the MDMA or related drug use, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with MDMA or related drug use).